Viewing Study NCT06262776


Ignite Creation Date: 2025-12-18 @ 8:55 AM
Ignite Modification Date: 2025-12-23 @ 9:03 PM
Study NCT ID: NCT06262776
Status: None
Last Update Posted: 2025-02-12 00:00:00
First Post: 2024-01-31 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients
Sponsor: None
Organization:

Study Overview

Official Title: Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (SIR ZOSTER)
Status: None
Status Verified Date: 2025-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SIR ZOSTER
Brief Summary: The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between kidney transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are:

1. Are there differences in vaccination immunological responses in kidney transplant patients on different immunosuppression regimens?
2. Are there differences in vaccination immunological responses between kidney transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: